Hyderabad, Dec. 23
AUROBINDO Pharma Ltd has announced that the USFDA has granted tentative approval for Stavudine oral solution of one mg.
The company in a statement said that this product will now be available for consideration for purchase under the President's Emergency Plan for AIDS Relief (PEPFAR).
With this approval, Aurobindo now has 9 products under PEPFAR.
The company stated that Stavudine Oral Solution is the first generic version approval of Zerit for Oral solution manufactured by BristolMyers Squibb.
This is a child-friendly product for paediatric use with HIV through to adolescence.
Stavudine is active against the human immunodeficiency virus (HIV) that causes AIDS.
This is used in combination with other agents for treatment of HIV-1 infection, a company statement said.